These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 122594)

  • 41. Development of immunotherapy for infections due to Pseudomonas aeruginosa.
    Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585
    [No Abstract]   [Full Text] [Related]  

  • 42. Pseudomonas immunoglobulin and vaccine in burn patients.
    Bose B
    Lancet; 1981 Feb; 1(8217):435. PubMed ID: 6110056
    [No Abstract]   [Full Text] [Related]  

  • 43. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
    Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
    Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
    Minukhin VV; Tsyganenko VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug; (8):42-5. PubMed ID: 3094301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low mortality in burned patients in a Pseudomonas vaccine trial.
    Jones RJ; Roe EA; Gupta JL
    Lancet; 1978 Aug; 2(8086):401-3. PubMed ID: 79764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutical pseudomonas aeruginosa antisera. Preparation, control and administration.
    Meitert T; Meitert E; Szegli G; Peligrad I
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):115-21. PubMed ID: 6816189
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunoprophylaxis of Pseudomonas aeruginosa.
    Young LS; Armstrong D; Markley K
    Ann Intern Med; 1971 Jun; 74(6):1012-3. PubMed ID: 4996343
    [No Abstract]   [Full Text] [Related]  

  • 51. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects].
    Stanislavskiĭ ES; Joó I
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccination for Pseudomonas aeruginosa.
    Alexander JW; Fisher MW
    Am J Surg; 1970 Oct; 120(4):512. PubMed ID: 4990276
    [No Abstract]   [Full Text] [Related]  

  • 53. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole cell heat-killed gram-negative bacilli vaccine.
    Waisbren BA; Martins RR; Bruns WT; Kurzynski TA
    Wis Med J; 1974 Apr; 73(4):S42-5. PubMed ID: 4206996
    [No Abstract]   [Full Text] [Related]  

  • 55. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-Pseudomonas immunoglobulin. IV. Combined anti-Pseudomonas immunoglobulin and Pseudomonas vaccine immunotherapy of burned patients--clinical investigations.
    Sakiel S; Schiller B; Buchowicz I; Lysakowska E; Tomanek E; Kruczałowa M; Przewdziecka M
    Arch Immunol Ther Exp (Warsz); 1984; 32(5):523-8. PubMed ID: 6534319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early protection by vaccines against Pseudomonas aeruginosa colonizing burns.
    Jones RJ; Lowbury EJ
    Br J Exp Pathol; 1972 Dec; 53(6):659-64. PubMed ID: 4630411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 60. Study of the immunogenicity of the Pseudomonas aeruginosa polyvalent corpuscular vaccine in human volunteers.
    Meitert E; Meitert T; Petrovici M; Sima F; Savulian C; Mitrică N; Georgescu C; Costache G
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):309-16. PubMed ID: 122593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.